Reminder of Shareholder Class Action Lawsuits
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy VTGN?
Source: Globenewswire
- Defendant Overview: CoreWeave, Inc. (CRWV) is accused of making false or misleading statements regarding its ability to meet customer demand between March 28, 2025, and December 15, 2025, with affected investors encouraged to seek lead plaintiff status by March 13, 2026.
- Customer Growth Allegations: Bath & Body Works, Inc. (BBWI) faces allegations of failing to disclose material facts about its customer base and net sales growth from June 4, 2024, to November 19, 2025, prompting affected investors to contact legal counsel before the March 13, 2026 deadline.
- Clinical Trial Risks: Vistagen Therapeutics, Inc. (VTGN) is involved in a lawsuit for not disclosing risks associated with its Phase 3 PALISADE-3 trial between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, for investors to apply for lead plaintiff status.
- Law Firm Background: Holzer & Holzer, LLC, recognized as a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by corporate misconduct, highlighting its significant role in the legal landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.596
Low
0.90
Averages
0.97
High
1.00
Current: 0.596
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by March 16, 2026, indicating significant legal risks for the firm.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the PALISADE-3 study failed to meet its primary endpoint, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Impact: The trial did not demonstrate a statistically significant improvement for fasedienol in treating social anxiety disorder, failing to show treatment differences from placebo on both primary and secondary endpoints, exacerbating investor concerns about the company's product pipeline.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in corporate and securities class litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise and influence in handling such cases.
See More
Faruqi & Faruqi Investigates Vistagen Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Vistagen Therapeutics for potentially misleading investors regarding the PALISADE-3 clinical trial, which may have led to significant financial losses due to inflated stock prices.
- Stock Price Plummet: On December 17, 2025, Vistagen announced that its PALISADE-3 study failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share, severely undermining investor confidence.
- Class Action Reminder: Investors are reminded to apply by March 16, 2026, to serve as lead plaintiffs in the federal securities class action against Vistagen, with Faruqi & Faruqi offering legal support to protect investor rights.
- Information Solicitation: Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to assist in the ongoing legal investigation, assuring that all communications will be kept confidential.
See More
Vistagen Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Vistagen Therapeutics for violations of securities laws, concerning trades made between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026, to participate.
- False Statements Allegation: The complaint alleges that Vistagen misled investors regarding the likelihood of success for its fasedienol drug candidate by falsely portraying positive results from the PALISADE-2 trial, thereby downplaying the risks of clinical study failures and causing investor losses.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action may remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for discussions about their rights, emphasizing the availability and importance of legal assistance in such matters.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiffs by March 16, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors.
- Case Background: The lawsuit alleges that Vistagen misled investors by issuing overly optimistic statements regarding its drug fasedienol's development while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Vistagen
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential securities fraud claims against Vistagen Therapeutics, Inc., particularly regarding misleading statements related to the failed PALISADE-3 clinical trial results announced on December 17, 2025, which have caused significant investor losses.
- Stock Price Plummet: Following Vistagen's announcement that its PALISADE-3 study did not demonstrate statistically significant improvement, VTGN's stock price fell over 81% at market open, exposing investors to severe depreciation risks on shares purchased at inflated prices.
- Class Action Deadline: Investors are reminded that the deadline to seek the role of lead plaintiff in the federal securities class action is March 16, 2026, and Faruqi & Faruqi encourages affected investors to contact them promptly to discuss their legal rights.
- Insufficient Disclosure: The complaint alleges that Vistagen and its executives violated federal securities laws by failing to disclose material adverse facts related to fasedienol, leading investors to purchase shares at artificially inflated prices, thereby impacting the company's market reputation and investor confidence.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by March 16, 2026, highlighting serious concerns over corporate governance and compliance.
- Stock Price Plunge: Following the December 17, 2025 announcement that the PALISADE-3 Phase 3 trial failed to show statistically significant improvement, Vistagen's stock plummeted by 80.25%, closing at $0.861 per share, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Trial Results Impact: The failure to meet the primary endpoint in the clinical trial, along with no significant difference observed in secondary endpoints, not only undermines investor confidence but may also adversely affect the company's future financing and research initiatives.
- Potential Legal Consequences: The class action lawsuit could expose Vistagen to substantial liability, exacerbating its financial pressures and potentially damaging its reputation and ability to raise capital in the market, necessitating close monitoring of developments.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by March 16, 2026, indicating significant legal risks for the firm.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the PALISADE-3 study failed to meet its primary endpoint, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Impact: The trial did not demonstrate a statistically significant improvement for fasedienol in treating social anxiety disorder, failing to show treatment differences from placebo on both primary and secondary endpoints, exacerbating investor concerns about the company's product pipeline.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in corporate and securities class litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise and influence in handling such cases.
See More
Faruqi & Faruqi Investigates Vistagen Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Vistagen Therapeutics for potentially misleading investors regarding the PALISADE-3 clinical trial, which may have led to significant financial losses due to inflated stock prices.
- Stock Price Plummet: On December 17, 2025, Vistagen announced that its PALISADE-3 study failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share, severely undermining investor confidence.
- Class Action Reminder: Investors are reminded to apply by March 16, 2026, to serve as lead plaintiffs in the federal securities class action against Vistagen, with Faruqi & Faruqi offering legal support to protect investor rights.
- Information Solicitation: Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to assist in the ongoing legal investigation, assuring that all communications will be kept confidential.
See More
Vistagen Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Vistagen Therapeutics for violations of securities laws, concerning trades made between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026, to participate.
- False Statements Allegation: The complaint alleges that Vistagen misled investors regarding the likelihood of success for its fasedienol drug candidate by falsely portraying positive results from the PALISADE-2 trial, thereby downplaying the risks of clinical study failures and causing investor losses.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action may remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for discussions about their rights, emphasizing the availability and importance of legal assistance in such matters.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiffs by March 16, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors.
- Case Background: The lawsuit alleges that Vistagen misled investors by issuing overly optimistic statements regarding its drug fasedienol's development while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Vistagen
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential securities fraud claims against Vistagen Therapeutics, Inc., particularly regarding misleading statements related to the failed PALISADE-3 clinical trial results announced on December 17, 2025, which have caused significant investor losses.
- Stock Price Plummet: Following Vistagen's announcement that its PALISADE-3 study did not demonstrate statistically significant improvement, VTGN's stock price fell over 81% at market open, exposing investors to severe depreciation risks on shares purchased at inflated prices.
- Class Action Deadline: Investors are reminded that the deadline to seek the role of lead plaintiff in the federal securities class action is March 16, 2026, and Faruqi & Faruqi encourages affected investors to contact them promptly to discuss their legal rights.
- Insufficient Disclosure: The complaint alleges that Vistagen and its executives violated federal securities laws by failing to disclose material adverse facts related to fasedienol, leading investors to purchase shares at artificially inflated prices, thereby impacting the company's market reputation and investor confidence.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by March 16, 2026, highlighting serious concerns over corporate governance and compliance.
- Stock Price Plunge: Following the December 17, 2025 announcement that the PALISADE-3 Phase 3 trial failed to show statistically significant improvement, Vistagen's stock plummeted by 80.25%, closing at $0.861 per share, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Trial Results Impact: The failure to meet the primary endpoint in the clinical trial, along with no significant difference observed in secondary endpoints, not only undermines investor confidence but may also adversely affect the company's future financing and research initiatives.
- Potential Legal Consequences: The class action lawsuit could expose Vistagen to substantial liability, exacerbating its financial pressures and potentially damaging its reputation and ability to raise capital in the market, necessitating close monitoring of developments.
See More
